Remove Drug Delivery Remove Drugs Remove Life Science
article thumbnail

Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

XTalks

Gelteq centers its technology on a proprietary, customizable gel platform designed for precise drug delivery, supporting prescription drugs, nutraceuticals, pet care and sports supplements. Priced at $4.0

article thumbnail

Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery

Bio Pharma Dive

The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The cluster effect: Connectivity and collaboration in life sciences hubs

Pharmaceutical Technology

From the Human Genome Project to contemporary drug development, collaboration is critical to the life sciences. It is also an important factor in the success of life sciences clusters, where a high concentration of pharmaceutical or medical device companies can all be found in one district, city or region.

article thumbnail

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

XTalks

Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drug delivery and drug-device combination product assembly in Rockford, Illinois.

article thumbnail

Polyrizon IPO Strengthens Momentum in Non-Invasive Drug Delivery Solutions

XTalks

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

article thumbnail

Kyowa Kirin backs €125m life science fund closed by Fountain Healthcare

pharmaphorum

Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – 25% ahead of its target – and says it will pump most of the money into European therapeutics and medical device companies. The third fund is now closed.

article thumbnail

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

BioTech 365

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of … Continue reading →